ArticleEJHaem2026
Validation of Gazelle Microchip Electrophoresis for Premarital Hemoglobinopathy Screening in Türkiye.
Article in EJHaem, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Hemoglobinopathies, the most prevalent recessive monogenic disorders globally, encompass thalassemia syndromes and structural hemoglobin variants, affecting approximately 5% of the world's population as carriers, with around 315,000 affected births annually. These conditions are especially common in regions including the Mediterranean Basin, parts of Africa, the Middle East, India, and Southeast Asia. Traditional screeningcomplete blood count (CBC), high-performance liquid chromatography (HPLC), and capillary electrophoresis (CE)followed by molecular genetic confirmation, requires skilled personnel and advanced facilities, which are often scarce in high-prevalence, low-resource areas, rendering them inaccessible to many. Gazelle, a novel, point-of-care (POC) microchip-based cellulose acetate electrophoresis platform, promises an affordable and accessible alternative for detecting common hemoglobin variants. Methods: This study evaluates Gazelle's performance against HPLC for premarital screening in Antalya, Türkiye, enrolling 616 participants: 516 for screening and 100 known carriers (81 beta-thalassemia, 19 sickle cell) as controls. Participants underwent CBC, HPLC, and Gazelle testing, with positive results confirmed by beta-gene sequencing. Results: Among the 516 screened (55.1% women, 44.9% men, average age 32.75 ± 11.25 years), 16 traits (3.2%) were identified, including 14 beta-thalassemia, one HbS, and one HbD. Statistical analysis confirmed 100% diagnostic agreement between Gazelle and HPLC. Conclusion: Gazelle's advantages include rapid results, digital storage, Wi-Fi connectivity, portability, and printed reports, which make it a transformative tool for identifying hemoglobin variants like HbA, HbS, HbF, and HbA2, and accurately detecting β-thalassemia carriers in resource-limited settings. Future efforts will focus on analytically validating Gazelle through evaluations of sample stability, operator variability, and repeatability/reproducibility in clinical settings to strengthen its positioning as a screening platform. Trial Registration: The authors have confirmed clinical trial registration is not needed for this submission.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.